November 8, 2023 03:45 PM ESTUpdated 04:36 PM
Pharma
FDA+
Marketing

FDA watch­dog ad­mon­ish­es Evofem for mar­ket­ing brochure for its con­tra­cep­tive Phexxi

Beth Snyder Bulik

Senior Editor

Evofem Bio­sciences last week re­ceived an un­ti­tled let­ter from the FDA, which cit­ed “mis­lead­ing” ben­e­fits in a mar­ket­ing brochure for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times